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Abstract 
The Great Debate session at the 2019 Melanoma Bridge congress (December 5‑7, Naples, Italy) featured counterpoint 
views from experts on five topical issues in melanoma. These were whether to choose local intratumoral treatment 
or systemic treatment, whether patients with stage IIIA melanoma require adjuvant therapy or not, whether treat‑
ment is better changed at disease progression or during stable disease, whether adoptive cell transfer (ACT) therapy 
is more appropriate used before or in combination with checkpoint inhibition therapy, and whether treatment can be 
stopped while the patient is still on response. As was the case for previous meetings, the debates were assigned by 
meeting Chairs. As such, positions taken by each of the melanoma experts during the debates may not have reflected 
their respective personal approach.
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Introduction
The Great Debate session at the 2019 Melanoma Bridge 
congress (December 5-7, Naples, Italy) featured counter-
point views from experts on five topical issues in mela-
noma. These were whether to choose local intratumoral 
treatment or systemic treatment, whether patients with 
stage IIIA melanoma require adjuvant therapy or not, 
whether treatment is better changed at disease progres-
sion or during stable disease, whether adoptive cell trans-
fer (ACT) therapy is more appropriate used before or 
in combination with checkpoint inhibition therapy, and 
whether treatment can be stopped while the patient is 
still on response. As was the case for previous meetings, 
the debates were assigned by meeting Chairs. As such, 
positions taken by each of the melanoma experts during 
the debates may not have reflected their respective per-
sonal approach.
Local or systemic treatment?
Sanjiv S. Agarwala: in favor of local treatment
Intralesional oncolytic therapy (ILOT) is the direct injec-
tion of tumors with agents that can result in local tumor 
regression and that may have a systemic effect that is 
also immunologically mediated [1]. ILOT can be viral-
based (e.g. talimogene laherparepvec [T-VEC], HF-10, 
coxsackievirus A21 [CVA21, CAVATAK™]), or non-
viral based (e.g. PV-10, interleukin [IL]-12). These agents 
can offer a high local concentration with palliation and 
symptom control and can also induce host immune anti-
tumor activity, augmenting the local response as well as 
providing a durable response in distant and non-injected 
regional metastases with limited systemic toxicity.
Clinical trials of T-VEC, CVA21 and PV-10 have 
demonstrated clinically significant, durable responses. 
In the phase III OPTiM trial, the primary end point 
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continuously ≥ 6 months) was significantly higher with 
T-VEC compared with GM-CSF ((16.3% [95% CI 12.1–
20.5] versus 2.1% [95% CI 0–4.5]; odds ratio [OR], 8.9; 
P < 0.001) in 436 patients with unresected stage IIIB-
IV melanoma and regional metastases [4, 5]. Overall 
response rate (ORR) was also higher in patients treated 
with T-VEC (26.4% versus 5.7%), with 41% of patients 
in the T-VEC group having a complete response (CR). 
Interim overall survival (OS) analysis also suggested a 
benefit with T-VEC, with median OS of 23.3  months 
versus 18.9  months with GM-CSF. This benefit was 
most pronounced in patients with stage IIIB/C, IVM1a 
disease. A second oncolytic virus is the naturally 
occurring common cold ICAM-1-targeted RNA virus, 
CVA21. In the phase II CALM study of 57 patients 
with stage IIIC-IV melanoma, the primary end point of 
investigator-assessed immune-related progression-free 
survival (PFS) at 6 months was 38.6% [4]. Median OS 
was 26 months and 1-year survival rate was 75.4%. ORR 
was 28.1% and responses were observed in injected 
lesions, non-injected non-visceral lesions and in distant 
non-injected visceral lesions.
PV-10 is a sterile, nonpyrogenic 10% solution of rose 
bengal disodium, a small molecule fluorescein deriva-
tive. In a phase II trial, ORR by-patient was 71% (CI 
51–87%) with 50% CR (CI 31–69%) in the subgroup of 
28 patients who received PV-10 into all existing mela-
noma lesions (i.e. no non-injected lesions) [3].
Intralesional therapy may also offer potential synergy 
when combined with systemic therapy. In particular, 
immune stimulation effected by intralesional agents 
may promote the release and presentation of tumor-
derived antigens which may synergise with the systemic 
effects of checkpoint inhibitor agents. Several ongoing 
clinical trials are assessing the potential of combin-
ing oncolytic immunotherapy with checkpoint inhibi-
tors. In a phase II trial of T-VEC in combination with 
ipilimumab versus ipilimumab alone, the combination 
resulted in a significantly higher ORR (39% versus 18%; 
OR, 2.9 [95% CI 1.5–5.5; P = 0.002) in 198 patients with 
unresectable stages IIIB-IV melanoma [8]. At three-
year follow-up, ORR remained significantly higher with 
the combination (36.7% versus 16.0%; OR, 3.0; 95% CI 
1.6–6.0; P = 0.002) [9]. Median PFS was 13.5  months 
with the combination and 4.5 months with ipilimumab 
alone and median OS was not reached in either arm. 
Total and activated CD8 T cells in the peripheral blood 
have been shown to increase after T-VEC administra-
tion and further increase after combined T-VEC and 
ipilimumab [37]. In a phase 1b/2 study of PV-10 in 
combination with pembrolizumab in patients with 
advanced cutaneous melanoma, safety and tolerability 
was acceptable with a CR rate for injected lesions of 
77% (3% partial response [PR]) achieved after a median 
of three injections/lesion [2].
Further potential for the intralesional approach is as 
neoadjuvant therapy in surgically resectable disease. In a 
phase II, randomized, open-label trial with T-VEC in 150 
patients with resectable stage IIIB, IIIC or IVM1a mela-
noma, the addition of neoadjuvant T-VEC improved two-
year recurrence-free survival (RFS) (hazard ratio [HR] 
0.75, P = 0.07) and OS (HR 0.49, P = 0.050) compared 
with surgery alone [10].
In favor of ILOT, monotherapy has been shown to be 
effective in locoregional disease while combination with 
immunotherapy has a synergistic effect without overlap-
ping toxicity and may reverse tumor resistance.
Olivier Michielin: in favor of systemic treatment
Although intratumoral therapy may be considered a new 
paradigm for cancer immunotherapy, it actually dates 
back to the late 19th century and ‘Coley’s toxins’ for the 
treatment of malignant tumors. However, there has been 
an increased focus on this area in the past decade with 
T-VEC therapy now approved and an integral part of our 
therapeutic options in inoperable stage III-IV melanoma. 
Despite this, more needs to be understood and prospec-
tively evaluated in order to make the best use of T-VEC 
and other intratumoral compounds in development.
In the phase II trial of T-VEC in combination with 
ipilimumab, although the primary endpoint of ORR did 
reach statistical significance with the combination versus 
ipilimumab alone, the secondary endpoints of PFS and 
OS were not significantly improved [9].
A successful intratumoral approach has several key 
requirements. These include the availability of accessible 
and injectable lesions, the potential for high local con-
centrations to be achieved with the delivery of adequate 
injection volume and the ability to reside in the tumor 
bed for sufficient time to produce a biological effect 
without diffusion out of the lesion. In addition, intratu-
moral agents should be able to overcome local resistance 
mechanisms, and have the ability to reprogram the tumor 
microenvironment (TME) and engage an abscopal effect.
An important consideration and potential limita-
tion of intratumoral therapy is the differential biology at 
the injection site and distant sites. Intratumoral injec-
tion must overcome immune local escape mechanisms 
but biology may be very different from that of the non-
injected lesion. Repertoire and activation status of T 
cells may vary and may or may not have a distant impact 
Fig. 1. T cell receptor repertoire heterogeneity within the 
tumor or between tumor sites was demonstrated within 
the TRACERx project, which showed that expanded 
T cell receptors can be subdivided into ubiquitous, i.e. 
those found in all tumor regions, and regional, i.e. those 
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present in a subset of tumor regions [26]. The number of 
ubiquitous and regional T cell receptors correlates with 
the number of ubiquitous and regional non-synonymous 
mutations, respectively. T cells elicited by intratumoral 
therapy and specific for regional mutations might not 
confer effective systemic immunity for the patient.
Another issue is that accessibility of lesions may very 
likely create a strong bias. Injection into subcutaneous 
and lymph node tumors may influence T cell repertoire 
and T cell homing capacity. Indeed, this process has been 
shown to be tightly pre-programmed and there are con-
cerns over intratumoral injections typically limited to 
superficial lesions.
The pharmacokinetics (PK) and pharmacodynamics of 
intratumoral injection may also represent a limitation of 
this approach. Local PK data can be very different from 
whole-body kinetics. For example, intratumoral injection 
of nivolumab involves diffusion to a near infinite dilution, 
with PK driven by off-rate and diffusion. Serum half-life 
for systemic nivolumab is 28 days but molecular dissocia-
tion half-life is around 2.7 h, meaning the effective intra-
tumoral concentration might be short-lived. However, 
it should be noted that such limitations are not present 
with intratumoral viruses.
A final consideration is where best to integrate intra-
tumoral therapies in the current treatment landscape. 
It may have an important role alone or in combination 
with checkpoint blockade in neoadjuvant therapy, help-
ing maximize the pathological CR rate and increasing 
the T cell repertoire. It may also be useful as a treatment 
for local relapse after adjuvant treatment. In patients 
with stage IV disease, intratumoral treatment may be an 
option when standard immunotherapy alone fails. How-
ever, tumor heterogeneity may be a limitation in this 
setting.
In conclusion, intratumor therapies have interesting 
properties, yet important aspects need to be addressed, 
including tumor heterogeneity and T cell repertoire, 
injection site bias and intratumoral PK/PD. More transla-
tional studies are needed to efficiently guide their clinical 
development and identify their optimal place in the rap-
idly evolving melanoma landscape.
Key points
• Clinical trials of ILOT (T-VEC, CVA21 and PV-10) 
have demonstrated clinically significant, durable 
responses.
• These agents induce host immune anti-tumor activ-
ity, augmenting the local response as well as provid-
ing a response in distant and non-injected regional 
metastases with limited systemic toxicity.
• The success of ILOT requires accessible and inject-
able lesions, the potential for high local concentra-
tions, the delivery of adequate injection volume and 
the ability to reside in the tumor bed for sufficient 
time.
• In addition, intratumoral agents should be able to 
overcome local resistance mechanisms, and have the 
Fig. 1 Clonal diversity, neo‑antigens and T cell repertoire in IT therapy
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ability to reprogram the TME and engage an absco-
pal effect.
• Immune stimulation effected by intralesional agents 
may synergise with the systemic effects of checkpoint 
inhibitor agents and clinical trials have indicated a 
synergistic effect that may reverse tumor resistance 
and without overlapping toxicity.
• More studies are needed to efficiently guide the clini-
cal development of ILOT and identify its optimal 
place in the rapidly evolving melanoma landscape 
(Fig. 2).
Do patients with stage IIIA disease really need 
adjuvant therapy?
Alexander Eggermont: Yes
The current situation with checkpoint inhibitors and tar-
geted treatments in the adjuvant setting directly parallels 
that previously seen in the advanced disease setting. The 
first adjuvant trial was with ipilimumab, which showed 
an absolute difference in survival of 11% versus placebo 
at both one and 5 years [12]. OS at 5years was 65% in the 
ipilimumab group compared with 54% in the placebo 
group (HR for death, 0.72; 95.1% CI 0.58–0.88; P = 0.001). 
This benefit was sustained long-term, with an 8.7% abso-
lute difference at 7 years for OS [13]. Targeted therapy 
with dabrafenib plus trametinib is also effective for 
patients with BRAF V600 mutant melanoma [25], with 
an estimated three-year recurrence-free survival (RFS) 
rate of 58% versus 39% with placebo (HR for relapse or 
death, 0.47; 95% CI 0.39–0.58; P < 0.001). However, unlike 
with ipilimumab, the survival benefit declines after the 
1st year and is not sustained longer-term. From about 
2years, immunotherapy offers a greater survival benefit 
than targeted treatment.
However, ipilimumab is not acceptable as adjuvant 
therapy because of the high rate of immune-related 
adverse events. Consideration of unacceptable side 
effects is more important in the adjuvant setting given 
that, depending on the risk of relapse and efficacy of the 
treatment, a subset of patients will not gain any benefit 
from treatment. In the adjuvant ipilimumab trial, many 
of the immune-related adverse events were grade 1–2 
thyroiditis which did not require intervention, but some 
were serious and chronic, including nephritis, colitis and 
insulin-dependent diabetes. Overall, 53% of patients dis-
continued because of toxicity.
Given the unacceptable toxicity of ipilimumab, the 
anti-PD-1 agents nivolumab and pembrolizumab repre-
sent more appropriate adjuvant treatment options. In the 
CheckMate-238 trial, the 1-year rate of RFS was 70.5% 
(95% CI 66.1–74.5) with nivolumab versus 60.8% (95% CI 
56.0–65.2) with ipilimumab (HR for disease recurrence 
or death, 0.65; 97.56% CI 0.51–0.83; P < 0.001) [50]. Treat-
ment-related grade 3–4 adverse events were reported in 
14% of the patients in the nivolumab group and in 46% 
of patients in the ipilimumab group. Similarly, pembroli-
zumab significantly increased one-year rate of RFS ver-
sus placebo (HR for recurrence or death, 0.57; 98.4% CI 
0.43–0.74; P < 0.001) in a phase III trial in 1019 patients 
[11]. Treatment-related grade 3–5 adverse events were 
reported in 14.7% of the patients in the pembrolizumab 
group.
In this trial, the 15-month incidence of immune-related 
adverse events was 37% with pembrolizumab versus 9% 
with placebo [15]. The incidence of adverse events with 
Fig. 2 Local or systemic treatment Audience response before and after debate
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pembrolizumab was 29% at 6months, so reducing treat-
ment duration to 6 months would not have a major 
impact on reducing adverse event rate or improving the 
risk: benefit ratio of treatment. However, the occurrence 
of an immune-related adverse event was significantly 
associated with a longer RFS in the pembrolizumab arm 
(HR 0.61), but not the placebo arm. Thus immune-related 
adverse events may be an indicator of a beneficial host 
immune response [15].
It is also important to consider the effect of adjuvant 
treatment in patients at different substages of stage III 
disease. Based on the American Joint Committee on 
Cancer (AJCC) 7th edition melanoma staging system [6], 
pembrolizumab prolonged RFS versus placebo in patients 
with stage IIIA melanoma (HR 0.32) as well as patients 
with stage IIIB (HR 0.57) and IIIC (HR 0.58) disease [14]. 
After reclassification of patients using the AJCC 8th edi-
tion melanoma staging system [19], the RFS benefit of 
pembrolizumab was similarly observed across AJCC-8 
stage III disease subgroups [14]. Based on these results, 
patients with stage IIIA disease, especially younger 
patients, should be considered for adjuvant treatment.
In patients with stage I-II disease, it is necessary to 
identify those patients at high-risk of relapse. More than 
50% of deaths due to melanoma occur in stage I/IIA 
sentinel lymph node biopsy (SLNB) negative patients, 
generally considered to be low risk, so there is a need 
to identify high-risk SLNB-negative patients. The Mayo 
Clinic CP-GEP model, currently in development for pos-
sible clinical use, combines clinical pathologic variables 
with a gene expression profiling algorithm of metas-
tasis predisposition genes and has been shown to be of 
potential prognostic benefit in identifying SLNB negative 
patients at risk of relapse [33, 34]. Use of a profiler may 
ultimately be informative for clinical decision-making.
The discussion whether all stage IIIA patients should be 
recommended adjuvant therapy is of course a risk:benefit 
ratio discussion. With relatively rare but potentially 
chronic immune-related adverse event, in a relatively low 
risk situation (especially in the AJCC-8 stage IIIA) the sit-
uation is clearly different for a patient aged over 70 years 
compared to a 25-year-old. The recommendations are 
clearly described in the most recently published guide-
lines [16, 17].
Jeffrey E. Gershenwald: No
In patients with AJCC 8th edition stage IIIA melanoma, 
adjuvant therapy may reduce the risk of recurrence and 
improve survival following initial treatment and in whom 
there is no evidence of disease. However, adjuvant ther-
apy can only provide a benefit if melanoma persists and 
can be of no benefit to patients with no risk of recur-
rent disease. Thus, a fraction of patients who receive 
adjuvant therapy have no potential benefit, but are still 
at risk of toxicity. Although relatively infrequent, adverse 
effects related to treatment can result in chronic life-long 
sequelae, which may be of particular concern in younger 
patients.
Implementation of the AJCC 8th edition melanoma 
staging system [19] that includes revisions to the defini-
tion and number of stage III stage groups, has impact 
on patient counseling and management, as well as con-
temporary adjuvant clinical trial design and assessment. 
Completion lymph node dissection (CLND) is no longer 
routinely offered as initial management for SLN-positive 
patients; nonetheless, it is important to note that accu-
rate nodal staging is still important in order to identify 
patients at risk of relapse. There is an at least theoreti-
cal concern that since CLND is no longer routinely per-
formed for the vast majority of SLNB-positive patients, 
some potentially clinically useful data, such as upstaging 
stage IIIA patients given that non-sentinel node involve-
ment is an independent predictor of poor survival, may 
impact on clinical decision-making. However, patients 
with AJCC 8th edition stage IIIA disease are overall 
unlikely to harbour tumor-involved non-SLNs if a CLND 
were to be performed, and so are very unlikely to be 
upstaged.
In the CheckMate-238 trial of nivolumab versus ipili-
mumab, no patients with AJCC 7th edition stage IIIA 
disease were included [Weber 2017], while the EORTC 
1325/KEYNOTE-54 trial of pembrolizumab included 
AJCC 7th edition stage IIIA patients but only those 
with > 1 mm metastasis in the sentinel node [11]. In the 
subgroup of patients with AJCC 7th edition stage IIIA 
disease, RFS at one-year was 89.8% with pembrolizumab 
and 76.8% with placebo (HR 0.32, 99% CI 0.09–1.23; 
P = 0.0217) [13]. When the trial was stratified accord-
ing to the new AJCC 8th edition melanoma staging sys-
tem, disease stage was prognostic but not predictive of 
response [13], which is not unexpected given that these 
pathological features have not previously been associ-
ated with response to anti-PD-1 therapy. Note that the 
AJCC 8th edition-staged patients from the trial are still 
relatively enriched for “higher risk” patients given the 
requirement that if they were AJCC 7th edition IIIA, the 
SLN metastasis had to have a tumor burden > 1  mm. In 
patients with AJCC 8th edition stage IIIB, a clear RFS 
benefit was observed. However, in patients with AJCC 
8th edition stage IIIA disease, although there appears to 
be a possible signal of RFS benefit, confidence intervals 
are wide and follow-up is thus far limited. As such, this 
should be considered very preliminary data for generally 
low-risk patients. Given that toxicity is not stage-specific, 
balancing the risk of serious toxicity versus potential 
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benefits becomes an increasingly important considera-
tion in this patient group.
The COMBI-AD study had similar eligibility crite-
ria for stage IIIA patients, i.e., SLN metastasis > 1  mm 
[28]. RFS benefit was observed across all AJCC 8th edi-
tion stage III subgroups, but the benefit was less clear in 
stage IIIA disease [22]. It also needs to be recognised that 
as the melanoma community considers treating earlier 
stage disease in the adjuvant setting, short-term follow-
up can be deceptive and a note of caution is required. It 
is important to emphasize that there was a variable and 
selective approach to adjuvant trial design, so that even 
within stage groups, patients were higher risk and rep-
resent enriched risk populations rather than a typical 
distribution.
The use of individualized risk models incorporating 
multiple features is becoming increasingly important. It 
is likely that we are entering an era in which decisions 
regarding adjuvant therapy will be based on these types 
of risk models that incorporate a multitude of clinico-
pathological and ultimately molecular and immune fac-
tors. There are already multiple high-quality biomarkers 
that can be integrated into risk models (e.g. primary 
tumor mitotic rate, SLN tumor burden, among others). 
Conventional staging will likely continue to inform deci-
sion-making but will not be a sole criterion.
To summarize, clinical benefit is only possible if resid-
ual subclinical disease exists. Toxicity may occur in any 
patient who receives adjuvant therapy, with the poten-
tial for life-long sequalae. The role of adjuvant therapy 
for patients with ‘low-risk’ stage IIIA disease continues 
to evolve and it may be better to reduce toxicity risk by 
minimizing potential overtreatment through the use of 
validated clinical tools and models. An overriding ques-
tion also remains—do we need to treat in the adjuvant 
setting, or can patients be treated only if and when mela-
noma ultimately recurs. Finally, the high financial cost of 
these treatments, both to the individual and at a health 
care provider level, is a very real concern.
Key points
• Several trials have now shown a benefit of checkpoint 
inhibitors as adjuvant therapy, with anti-PD-1 inhibi-
tion more acceptable due to lower toxicity than ipili-
mumab.
• Targeted therapy with dabrafenib plus trametinib is 
also effective, but the survival benefit is not sustained 
longer-term and immunotherapy offers a greater sur-
vival benefit from about 2 years.
• The benefit of PD-1 blockade is observed across 
AJCC-8th edition stage III disease subgroups and 
patients with stage IIIA disease, especially younger 
patients, should be considered for adjuvant treat-
ment.
• However, adjuvant therapy can only provide a benefit 
if melanoma persists and is of no benefit to patients 
with no risk of recurrent disease. Balancing the risk 
of serious toxicity versus potential benefit is espe-
cially important in stage IIIA patients.
• Although infrequent, adverse effects related to treat-
ment can result in chronic life-long sequelae, which 
may be a particular concern in younger patients.
• Decisions regarding adjuvant therapy will increas-
ingly be based on risk models that incorporate a mul-
titude of clinicopathological as well as molecular and 
immune factors (Fig. 3).
When is the best time to change treatment 
on anti‑PD1 therapy: at disease progression 
or during stable disease?
Michael Postow: in favor of switching at disease 
progression and not stable disease
One argument for switching systemic therapy at disease 
progression rather than during stable disease (SD) is 
that patients with SD can have prolonged SD. Looking 
at patients treated with nivolumab, many patients with 
SD, which included some with significant tumor shrink-
age, remain stable for a sustained period and did not 
ultimately progress [48]. Moreover, an analysis of pooled 
data from the KEYNOTE-001 and 006 trials of pembroli-
zumab showed similar OS outcomes at 5 years whether 
patients had a partial response (PR) or SD at week 24 
[20]. As would be expected, complete responders at week 
24 did better than patients with PR/SD. Given that treat-
ment for responders would not be switched, there does 
not seem a valid rationale for switching patients with SD 
after 24 weeks from start of therapy.
Patients with SD should also not switch based upon 
their week 12 assessment. Although overall survival out-
comes for patient with SD at week 12 do look worse than 
patients with PR or CR at week 12, there are patients 
with SD at week 12 who become responders by week 24, 
and, as mentioned, above, if patients with SD at week 12 
remain SD at week 24, their long term OS appears similar 
to patients with PR. Overall, these data in aggregate are 
insufficient to recommend patients with SD at week 12 
should switch therapy.
In addition, no multivariable analysis has been per-
formed on the apparent association between tumor 
response and overall survival. In fact, response was 
shown to be related to known prognostic factors, includ-
ing baseline tumor size, ECOG performance status and 
metastatic stage. Therefore, the apparent finding that SD 
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patients have lower OS than patients with PR/CR may be 
confounded by worse prognostic features.
Furthermore, second-line therapy after PD1 progres-
sion can still be effective. There is no clinical evidence 
that second-line therapy is less effective if used to treat 
patients after disease progression rather than patents 
with prior SD on anti-PD1. Ipilimumab has been shown 
to be just as effective after anti-PD-1 therapy as before, 
with response rates of 10–15% [51], and response rates 
to anti-PD-1  s are similar whether before or after ipili-
mumab [21]. Anti-PD-1  s also show similar outcomes 
when used after progression on ipilimumab with or with-
out BRAF inhibitors [27]. Moreover, switching from anti-
PD-1 s to BRAF/MEK inhibitors can be associated with 
significant toxicity problems involving treatment inter-
ruption or dose reductions [40]. Thus, switching patients 
with SD has the potential of causing toxicity issues before 
such a change in systemic therapy is truly needed.
To conclude, SD on anti-PD-1 therapy should not be 
considered a terrible event. The apparent inferior OS 
outcomes could all be due to the simple fact that patients 
with SD have a worse prognosis at baseline compared to 
patients who have a CR or PR. Patients with SD 24 weeks 
into anti-PD1 agents have the same overall survival as 
responders, and since we do not know who these patients 
are at week 12, patients with SD should not be switch to 
other therapy at week 12 as well. Second-line therapies 
can still be effective after disease progression and there 
are no data that suggest treatment intensification or 
switch at SD improves outcomes compared to changing 
therapy at PD.
Omid Hamid: in favor of switching during stable disease
Although it may be true that the majority of patients with 
CR are those with a low tumor burden, these patients 
typically progress to high tumor burden and M1C dis-
ease. We also do not have many treatment options post-
PD-1 progression and it is not possible to return patients 
to the same stage they were previously at after the disease 
has progressed.
In the analysis of data from the pooled KEYNOTE-001 
and 006 trials of pembrolizumab, patients with SD at 
week 12 but no response or progression at weeks 18 or 24 
are more relevant to this argument than those with SD at 
week 12 and a subsequent response at week 18 or 24. In 
these patients, OS rates decline rapidly from2 years with 
a survival rate of around 50% after 5 years. Similarly, with 
nivolumab plus ipilimumab, OS in patients with stable 
disease is only 50% at 2 years [29] and there is a higher 
rate of CR and PR in patients alive at 5 years. In patients 
treated with dabrafenib plus trametinib, OS at 2 years for 
those with SD as best response was only 29% [35]. These 
are not great outcomes and it is important to understand 
why these patients are not doing better.
In a retrospective analysis of patients with advanced 
BRAF-mutant melanoma, switching from targeted ther-
apy to checkpoint inhibitors during ongoing response 
resulted in an OS benefit compared with switching at 
time of disease progression [38]. However, no significant 
correlation was seen between time of switching and PFS 
or response rates to checkpoint inhibitor therapy.
There are more accurate means to assess how patients 
with SD are actually responding to treatment. Vari-
ous imaging modalities may help predict outcomes. 
In a retrospective analysis of patients treated with 
Fig. 3 Do patients with stage IIIA disease really need adjuvant therapy? Audience response before and after debate
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anti-PD-1-based immunotherapy, [18F]2-fluoro-2-de-
oxy-d-glucose positron emission tomography (FDG-
PET) imaging better predicted long-term outcomes 
compared with standard computed tomography (CT) 
response criteria [46]. Non-invasive PET imaging of T 
cells can be used for cancer diagnostics, disease moni-
toring, and patient stratification. PET Response Crite-
ria in Solid Tumors (PERCIST) 1.0 have been shown to 
be more sensitive and accurate than RECIST 1.1 for the 
detection of an early therapeutic response to chemother-
apy in patients with non-small-cell lung cancer (NSCLC) 
[43]. In melanoma, complete metabolic response in the 
first BRAF/MEK inhibition treatment cycle predicted 
OS in patients with advanced BRAF-mutant disease [32]. 
Circulating tumour DNA (ctDNA) analysis may also pre-
dict relapse following resection in stage II-III melanoma 
[47] and studies have reported that ctDNA detection is 
associated with clinical outcomes across cancer types. 
These assessments should be included with current man-
agement paradigms; early evaluation with biopsy and 
ctDNA analysis supported by imaging can help in treat-
ment switching decision-making. Further randomized 
trials will also help reveal the optimal time for switching 
and best overall treatment strategy.
Key points
• SD may be considered a positive response and a 
reflection of poor prognostic features and may not 
itself may not be independently associated with a 
poor outcome.
• Patients with SD may remain stable for a sustained 
period and not ultimately progress and long-term OS 
outcomes may be irrespective of response at week 24.
• Second-line therapy can be as effective if used to 
treat patients after disease progression rather than 
patents with SD.
• Moreover, switching therapy (e.g. from anti-PD-1  s 
to BRAF/MEK inhibitors) can be associated with sig-
nificant toxicity problems.
• However, there are limited treatment options post-
PD-1 progression and it is not possible to return 
patients to the same stage they were previously after 
progression.
• Other approaches to assess how patients with SD are 
actually responding may be more useful for treat-
ment switching decision-making, e.g. ctDNA analysis 
and imaging (Fig.  4).
Adoptive cell transfer before or in combination 
with checkpoint inhibitors
Hassan M. Zarour: in favor of before
Evidence for ACT utilizing tumor-infiltrating lympho-
cytes (TILs) in melanoma is encouraging with multiple 
clinical trials reporting response rates of approximately 
40–50% with 10–20% CRs. These responses have been 
shown to be durable and have been observed in both 
treatment-naïve and refractory patients.
C-144-01 is a phase II trial of ACT using lifileucel 
(LN-144) in patients with stage IIIc-IV metastatic mela-
noma who have received at least one prior treatment 
Fig. 4 When is the best time to change treatment on anti‑PD1 therapy: at disease progression or during stable disease? Audience response before 
and after debate
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with systemic therapy including an immune checkpoint 
inhibitor. In 42 primary refractory patients enrolled in 
the trial, with a best response of progressive disease 
(PD) on their first anti-PD-1/L1 treatment, an ORR of 
41% was observed  [41]. Responses were durable with 
median duration of response not reached after one year 
of follow-up.
In an earlier trial, 80 patients with stage IV melanoma 
were enrolled, of which 57 were treated with ACT and 23 
were withdrawn mainly due to clinical deterioration dur-
ing TIL preparation i.e. 28% drop-off [7]. Although ORR 
was 40% for treated patients, this was reduced to 29% for 
all enrolled patients. This trial also provided evidence 
that anti-CTLA-4 therapy after ACT provides clinical 
benefit, with three of 19 (16%) patients who received ipil-
imumab after TIL therapy experiencing ongoing CRs.
ACT of TILs has many challenges. It is very expensive 
and requires technical expertise. There are also issues 
over the time required to generate TILs; this is typically 
4–8  weeks during which time some patients may pro-
gress. In addition, the rate of success in generating TILs 
may vary, although is usually > 75% so is not generally 
a limiting factor. Most of the data are from small stud-
ies and non-randomized trials and a prospective rand-
omized study is required.
The optimal clinical setting for ACT in melanoma is 
also unclear. Treatment-naïve patients have many potent 
treatment options, including checkpoint blockade, so 
this does not appear to be an appropriate setting. A more 
logical place is in anti-PD-1 and targeted treatment-
refractory patients. However, the question of whether 
PD-1 therapy before ACT would improve its efficacy is 
currently unknown, with no clear evidence in the litera-
ture. In fact, it has also recently been reported that PD-1 
blockade in sub-primed CD8 cells induces anti-PD-1 
therapy resistance through the induction of dysfunc-
tional PD-1+CD38hi cells [49]. In inflamed tumors, ACT 
may not be needed since various therapies can be used 
to overcome resistance mechanisms. However, ACT 
may be important when T-cells cannot reach the tumor 
i.e. in immune-excluded or immune-desert phenotypes. 
In these settings, the rationale for combined therapy to 
improve ACT goes beyond immune checkpoint blockade 
and additional strategies to allow T cell infiltration into 
the tumor may be required.
Igor Puzanov: in favor of combination
CD19-engineered CAR-T cells are clinically active, espe-
cially in liquid tumors, although not all patients achieve 
durable responses and toxicity (e.g. cytokine-release syn-
drome, neurotoxicity) may be an issue. In solid tumors, 
CAR-T cells need to successfully traffic from the blood 
into solid tumor sites, despite potential T cell chemokine 
receptor-/tumor-derived chemokine mismatches, as 
well as infiltrate the stromal elements of tumors in 
order to elicit tumor-associated antigen (TAA)-specific 
cytotoxicity, regardless of antigen loss or heterogene-
ity. Even after successful trafficking and infiltration, T 
cells become rapidly dysfunctional owing to a hostile 
TME, that can include oxidative stress, hypoxia and the 
presence of inhibitory soluble factors and cytokines, 
suppressive immune cells, Tregs, and myeloid derived 
suppressor cells (MDSCs), and T cell-intrinsic negative 
regulatory mechanisms, e.g. checkpoint inhibitory recep-
tors. CAR-T cells themselves also have the potential for 
immunogenicity and toxicity.
Various strategies may be adopted to help overcome a 
hostile TME. CAR-Ts that deplete fibroblast cells, or that 
degrade the extracellular matrix can overcome physical 
and metabolic barriers. CAR-Ts that interrupt inhibitory 
adenosine and PGE2 signaling, and CAR-Ts expressing 
dominant negative TGFβ can be used to prevent inhi-
bition by tumor-derived soluble factors and cytokines. 
The presence of immunosuppressive immune cells may 
be addressed by the simultaneous depletion of MDSCs 
and Tregs e.g. through the use of alternative homeo-
static cytokines, such as IL-7 and IL-21, to boost CAR-T 
efficacy without stimulating Tregs. Intrinsic regulatory 
mechanisms of T cells may be overcome by combin-
ing CAR-T therapy and PD-1 blockade, the use of PD-1 
switch receptors to neutralize inhibitory PD-1 signaling, 
blocking CTLA-4 enhanced adoptive transfer, or engi-
neering CAR-T cells lacking inhibitory molecules (e.g., 
diacylglycerol kinase).
Generating CAR-T cells can take 3–4 weeks but many 
patients expect immediate treatments. Because of this, 
anti-PD-1 may be given to bridge the gap before the 
CAR-T cells are available. However, PD-1 blockade prior 
to antigen priming with cancer vaccine can abrogate 
the anti-tumor immune effect [49]. In a murine model, 
HPV16 E7 tumor vaccine or anti-PD-1 alone had little 
effect on tumor volume while the combination of vac-
cine and anti-PD-1 significantly reduced tumor burden. 
However, starting anti-PD-1 therapy before the vaccine 
abrogated the beneficial effect of the combination. A sim-
ilar effect was seen with regard to survival. Although this 
scenario involved using a vaccine in a murine model, this 
may have clinical relevance to how ACT and immuno-
therapy may interact in patients.
In addition, simultaneous addition of anti-PD-1 
negated the antitumor effects of the vaccine with anti-
OX40 antibody in mice [44]. Vaccine plus anti-OX-40 
produced a tumor response. However, when anti-PD-1 
was added, antigen-specific CD8 + T-cell tumor infiltra-
tion, antitumor response and survival were all reduced, 
indicating that anti-PD-1 added at the start of therapy 
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exhibits a detrimental effect. Addition of anti-PD-1 later 
i.e. end of treatment sequence, was not detrimental but 
was not associated with any additional improvement in 
tumor volume.
In practice, many patients eligible for ACT will have 
previously received anti-PD-1 therapy. Given this, the 
use of anti-PD-1 s after ACT may not be of major clini-
cal utility. CAR-T therapy may have significant toxicity, 
both on-target off-tissue cross-reactions when a targeted 
tumor antigen is also expressed on other tissues and off-
target cross-reactions that occur when the engineered 
receptor cross-reacts with an unanticipated stereochemi-
cally-related antigen that is present on an essential tissue. 
The financial toxicity of CAR-T may also be a problem 
for many patients. To conclude, anti-PD-1/PD-L1 should 
be an automatic backbone for checkpoint inhibitor-based 
therapy, and combinations with other modalities, includ-
ing CAR-T and other cell therapies needs to be devel-
oped in a rational manner.
Key points
• Evidence for ACT utilizing TILs in melanoma is 
encouraging with multiple clinical trials report-
ing response rates of approximately 40–50% in both 
treatment-naïve and refractory patients.
• Treatment-naïve melanoma patients have many 
treatment options, including checkpoint blockade, so 
this does not appear to be an appropriate setting and 
so use in anti-PD-1 and targeted treatment-refrac-
tory patients may be more logical.
• Anti-PD-1 may be given to bridge the gap before the 
CAR-T cells are available. However, PD-1 blockade 
prior to antigen priming with cancer vaccine can 
abrogate the anti-tumor immune effect in mice, and 
may have clinical relevance to how ACT and immu-
notherapy are combined.
• In practice, many patients eligible for ACT will have 
previously received anti-PD-1 therapy so the use of 
anti-PD-1  s after ACT may not be of major clinical 
utility.
• ACT may be important when T-cells cannot reach 
the tumor i.e. in immune-excluded or immune-
desert phenotypes.
• Anti-PD-1/PD-L1 should be the backbone of ther-
apy, and combinations with other modalities includ-
ing ACT need to be developed in a rational manner 
(Fig. 5).
Can we stop treatment while on response?
Jean‑Jacques Grob: Yes
Even a short duration of immunotherapy can modulate 
the TME and activate an active immune reaction which 
may be durable. Moreover, there is concern that over-
activation of the immune system via long-term inhibition 
of PD-1/PD-L1 may be deleterious by leading to immune 
exhaustion. thereby allowing tumor growth as well as 
compromising self-tolerance and inducing chronic auto-
immune disease. There are also societal concerns regard-
ing the sustainability, financial cost and burden on the 
healthcare system of chronic long-term immunother-
apy. Given all these factors, stopping checkpoint block-
ade while patients are on response may be potentially 
Fig. 5 Adoptive cell transfer before or in combination with checkpoint inhibitors Audience response before and after debate
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beneficial. However, the evidence for such an approach is 
limited.
Data from the adjuvant setting suggests stopping treat-
ment while on response may be possible, since the differ-
ence in RFS between PD-1 treatment and control arms 
in adjuvant trials is accounted for by those patients who 
respond, discontinue on response after 1year and are still 
responding [11]. Although there is no randomized trial 
in metastatic melanoma, discontinuation of nivolumab 
after 1year in patients with metastatic NSCLC resulted in 
worse PFS compared with continuous nivolumab treat-
ment [45]. However, the PFS plateau of PFS in the one-
year treatment arm shows that discontinuation did not 
compromise benefit in a subset of patients. Retrospective 
analyses of metastatic melanoma trials, and real-world 
data also suggest that benefit can be maintained after 
stopping treatment. In exploratory analysis of the KEY-
NOTE-006 trial, 86% of patients who completed 2 years 
on pembrolizumab were progression-free at 20  months 
after end of therapy [30]. In clinical practice, a study 
across 14 centers in Europe and Australia reported dis-
ease progression in only 40 of 185 (22%) patients who dis-
continued pembrolizumab or nivolumab in the absence 
of disease progression or treatment-limiting toxicity [24].
There are also criteria which can help select the best 
patients for safe discontinuation. Intensity of response 
to anti-PD-1 treatment is a prognostic marker and pro-
longed PFS can be expected in patients with a CR or PR 
who do not progress before 2–3 years [24, 30]. Discontin-
uation after CR has been shown to be safe; among com-
plete responders, only 4 of 67 (6.0%) who discontinued 
pembrolizumab for reasons other than progression had 
disease progression in the KEYNOTE-001 trial [39]. The 
24-month disease-free survival (DFS) rate from time 
of CR in the 67 patients was 90%. In patients treated 
with nivolumab plus ipilimumab, severe toxicity may be 
indicative of who will have a durable benefit. In trials of 
nivolumab plus ipilimumab, patients who discontinued 
for toxicity in the induction phase had comparable PFS 
and OS to those who did not discontinue due to treat-
ment-related adverse events [23, 42].
Finally, stopping while on response is an option 
because there is a chance for rescue via rechallenge with 
anti-PD-1 s, surgery/stereotactic radiosurgery or BRAF/
MEK inhibitor treatment in patients who relapse after 
discontinuation.
However, even in the best situation there is always a 
risk. Some relapses may be immediately life-threatening 
(e.g. brain metastasis) and the efficacy of rechallenge, or 
a new therapy line is never guaranteed. The acceptance 
of this risk by the patient is crucial in any decision to stop 
treatment.
Although discontinuation of checkpoint inhibition may 
be appropriate in the right situation, the same cannot be 
said of targeted therapy. Cessation of BRAF/MEK inhibi-
tion will result in tumor progression in most cases when 
the tumor has not been eradicated. In addition, second-
ary adaptive resistance will develop in most patients at 
some stage. However, short discontinuation periods are 
common to manage toxicity and do not seem to reduce 
the benefit so intermittent treatment may be consid-
ered but this requires validation. There may also be a 
Fig. 6 Ongoing trials of BRAF/MEK inhibitor therapy as a starter before immunotherapy
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biological rationale for using BRAF/MEK inhibition as 
an induction treatment before anti-PD-1 immunotherapy 
but this also requires validation and is being assessed in 
ongoing trials Fig. 6.
Omid Hamid: No
The evidence in favour of stopping treatment while on 
response is weak. Landmark analysis reveals that some 
patients exhibit sustained durable responses to immune 
checkpoint inhibitors resulting in prolonged treatment-
free intervals. Evidence to support that stopping treat-
ment mitigates potential toxicities is limited and financial 
burden of treatment should not be the primary concern 
from a clinician’s perspective.
The CheckMate-153 randomized trial showed a signifi-
cant PFS benefit in patients with advanced NSCLC who 
were randomized to continuous nivolumab and were 
still on treatment at 1-year versus one-year fixed dura-
tion nivolumab [HR 0.42, 95% CI 0.25–0.71] [45]. PFS 
from randomization favored continuous nivolumab for 
all subgroups. OS also showed a trend that favored con-
tinuous nivolumab. In the group that stopped nivolumab 
at one-year, 43 of 87 (49%) who had a response or SD at 
randomization had disease progression. Of these, 34 were 
retreated with nivolumab, meaning some patients were 
never retreated. Among retreated patients, responses 
were not that durable and most showed an increase in 
tumor burden.
Intermittent checkpoint inhibitor therapy may be 
an option. In patients with metastatic renal cell carci-
noma (RCC), those who achieved ≥ 10% reduction in 
tumor burden on nivolumab entered a treatment-free 
observation phase with reimaging every 12 weeks [36]. 
Nivolumab was restarted in patients with a ≥ 10% tumor 
burden increase and again held when tumor burden 
reduction was ≥ 10%. Of the 14 patients, five (36%) met 
the criteria for the intermittent phase and of these one 
needed to restart therapy and the other four had a sus-
tained response off therapy.
Discontinuation of anti-PD-1 therapy is also a topic in 
debate in hematological malignancies. In a study of 32 
patients with Hodgkin’s lymphoma, 23 discontinued anti-
PD-1 treatment after a median duration of 14.6 months 
due to prolonged response and nine because of unaccep-
table toxicity; 29 had a CR at time of discontinuation [31]. 
If discontinuation was an effective strategy, then it seems 
probable that it would most likely work in Hodgkin’s 
lymphoma, in which responses are typically deep and 
durable. However, after a median of 20.8  months from 
anti-PD-1 discontinuation, more than a third (n = 11) of 
patients had relapsed/progressed. Of the 29 patients who 
were in CR at the time of anti-PD-1 discontinuation, esti-
mated 2-year DFS rate was 65% (95% CI 9: 46.6–88.7%). 
All three patients who were in PR at the time of anti-
PD-1 discontinuation had relapsed. Increased risk of 
relapse at 12 months was based on three main character-
istics: the absence of complete metabolic response at the 
end of anti-PD-1 treatment, prolonged time to achieve 
best overall response, and older age.
Concerns over increased toxicity with long-term treat-
ment is also probably overstated. In a 5-year analysis 
of patients with advanced NSCLC treated with pem-
brolizumab in the KEYNOTE-001 study, incidence of 
immune-mediated adverse events was similar after three 
and 5years with little evidence of late-onset or new toxic-
ity [18].
Fig. 7 Can we stop treatment while on response? Audience response before and after debate
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In conclusion, arguments for stopping therapy on 
response based on cost or toxicity appear to be weak and 
options for second-line therapy after progression on anti-
PD-1 therapy are generally poor. Data from other solid 
tumors is generally against stopping treatment. It may 
be an option to individually tailor treatment for selected 
patients but in general therapy should only be stopped to 
start another treatment line.
Key points
• Even a short duration of immunotherapy can acti-
vate an active immune reaction which may be dura-
ble while over-activation via long-term inhibition of 
PD-1/PD-L1 may be deleterious.
• There are also societal concerns regarding the sus-
tainability, financial cost and burden on the health-
care system of chronic long-term immunotherapy.
• Given this, stopping checkpoint blockade while 
patients are on response may be possible, although 
the evidence for such an approach is weak.
• Criteria may be able to help select the best patients 
for safe discontinuation e.g. intensity of response, but 
even in the best situation there is always a risk which 
needs to be explained to the patient.
• Although discontinuation of checkpoint inhibition 
may be appropriate in the right situation, the same 
cannot be said of targeted therapy with cessation 
resulting in tumor progression in most cases when 
the tumor has not been eradicated (Fig. 7).
Conclusions
Counterpoint views from leading experts on five con-
troversial clinical issues on Melanoma’s treatment were 
presented during these Great Debate sessions. Given the 
constraints of the format and the intended nature of the 
session, each presentation was not intended as a rigorous 
assessment of the field but rather provided an opportu-
nity to highlight some important areas of debate. It may 
be that there are no clear right or wrong answers to these 
questions; however, it is hoped that these discussions can 
help focus attention on these issues, stimulating further 
debate and encouraging the research needed to improve 
our understanding of different therapeutic approaches 
and thereby further improve outcomes for patients.
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